Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.

A patient's grey hair regained color during treatment with adalimumab.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Upadacitinib may effectively treat resistant lichen planopilaris.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Anti-CD19 therapy may help treat SLE and NMOSD.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

CS12192 effectively treats alopecia areata with better safety than current options.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

JAK inhibitors show promise for treating various skin diseases.

Ritlecitinib is an effective new treatment for Alopecia Areata.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Mogamulizumab can cause hair loss and skin rashes.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.